Study on the binding of novel antitumor drug Ethaselen to bovine serum albumin

Abstract

Abstract: The binding pattern of Ethaselen to bovine serum albumin (BSA) was studied by fluorescence spectroscopic technique and Autodock 3.0.5 analysis. The result showed that the binding constant K of Ethaselen and BSA is 3.5×10⁴L/mol and the number of binding sites n = 0.9. The binding between Ethaselen and BSA or human serum albumin (HSA) is mainly through hydrophobic interactions.

Key words: Bovine serum albumin, Bovine serum albumin, Ethaselen, Ethaselen, Binding, Binding

CLC Number:

R916

R978.7

Supporting:

Cite this article

Wan-Chen Tang, Ge Fu, Xu Wang, Jian-Guo Zhang, Hui-Hui Zeng^*. Study on the binding of novel antitumor drug Ethaselen to bovine serum albumin [J]. .

share this article

0
/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: http://jcps.bjmu.edu.cn/EN/

http://jcps.bjmu.edu.cn/EN/Y2009/V18/I2/128

References

[1] Zhao, F.; Yan, J.; Deng, S.J.; Lan, L.X.; He, F.; Kuang, B.; Zeng, H.H. Cancer Lett. 2006, 236, 46-53.

[2] Zhou, H.Y.; Dou, G.F.; Meng, Z.Y.; Lou, Y.Q.; Zhang, G.L. J. Chromatogr. B. 2007, 852, 617-624.

[3] Yue, Y.Y.; Zhang, Y.H.; Qin, J.; Chen, X.G. J. Mol. Struct. 2008, 888, 25-32.

[4] Wang, T.; Xiang, B.R.; Wang, Y.; Chen, C.Y.; Dong, Y.; Fang, H.S.; Wang, M. Colloid Surf. B. Biointerfaces. 2008, 65, 113-119.

[5] Ross, P.D.; Subramanian, S. Biochemistry. 1981, 20, 3096-3102.

Related Articles 15

[1]	Kai Li, Bingjie Tang, Xinlong Chai, Yang Ping, Lihong Wang, Jin Su. Sialic acid-functionalized targeted drug delivery systems: advances in tumor and inflammation therapy by binding to Siglecs or selectin receptors [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(10): 773-795.
[2]	Xing Sun, Changyong Yang, Kan Lin, Caihong Zhou, Chen Liao, Limin Zhang, Xinsheng Jin, Langyong Mao, Hua Ying, Weikang Tao, Lianshan Zhang. Camrelizumab (SHR-1210), a humanized anti-PD-1 IgG4 mAb, exhibits superior anti-tumor activity and a favorable safety profile in preclinical studies [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(5): 393-408.
[3]	Wenwen Cheng, Dongmei Zhang, Qiang Zheng, Zhongjun Li, Xiangbao Meng. Design, synthesis and biological evaluation of novel HDAC inhibitors: sulphur-containing zinc binding groups [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(6): 408-421.
[4]	Bo Han, Fei Long, Wei Yu, Wen Chen, Xinchun Wang, Gang Guo, Liangxue Zhou. Interaction of isoliquiritigenin with bovine serum albumin studied by fluorescence quenching method [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(3): 196-200.
[5]	Wenfang Huang, Cangman Zhang, Sensen Li, Yi Liang, Hong Wang, Shizhong Chen. On-line HPLC-DAD coupled with ESI-IT-TOF-MS and fluorescence detection to identify DNA-binding compounds from Lithospermum erythrorhizon using acridine orange as the fluorescence probe [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(9): 581-590.
[6]	Sujit Nair, Celine Liew, Tin Oo Khor, Li Cai, Ah-Ng Kong . Differential signaling regulatory networks governing hormone refractory prostate cancers [J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(8): 511-524.
[7]	Kun Xiong, Wei Xu, Huihui Zeng* . Reactive oxygen species mediate ethaselen-induced rapid apoptosis in A549 cells [J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(1): 54-59.
[8]	Luyong Zhang, Miao Zhang, Haixia Qiu, Ying Gu^, Jingquan Zhao^. Site- and orientation-specific binding of hematoporphyrin monomethyl ether to human serum albumin revealed by single spectral kinetic parameter [J]. Journal of Chinese Pharmaceutical Sciences, 2013, 22(6): 491-495.
[9]	Meng Wang, Lei Xing, Shifang Lu, Zhu Guan^*, Zhenjun Yang, Lihe Zhang. Synthesis and the anti-HIV activity of novel dinucleotides containing L-isonucleosides [J]. , 2013, 22(4): 314-318.
[10]	Aihua Liu, Yuanjun Zhu, Xiaoyan Liu, Yinye Wang^*. Expression, purification and evaluation of N-terminal domain of AcAP5 with Factor Xa inhibitory activity [J]. , 2013, 22(3): 268-271.
[11]	Long Ren, Ning Jiao^*. A perspective on picornavirus inhibitors and concrete evolution of WIN compounds [J]. , 2012, 21(6): 509-525.
[12]	Su Chen, Ping Song, Ying Wang, Qi-Zhi Hu, Xuan Zhang^*, Qiang Zhang. Development of an HPLC-UV method for the determination of ethaselen in its injection formulation [J]. , 2012, 21(4): 321-326.
[13]	Jia-Ning Fu, Jing-Yu Wang, Li-Hui Wang, Lei Wang, Wan-Chen Tang, Gao-Xiong Cai, Mi Liu, Hui-Hui Zeng^* . Drug efficacy and pharmacological action of an organoselenium compound ethaselen, a novel antitumor drug [J]. , 2010, 19(3): 163-168.
[14]	Qing Yang, Ji-Rang Zhu, Qi Sun^, Jing-Rong Cui, Run-Tao Li, Ze-Mei Ge^ . A novel class of cyclophosphamide prodrug: structure-activity relationships of cyclophosphamide piperaziniums [J]. , 2010, 19(1): 24-33.
[15]	Jing Li, Jia-Ning Fu, Qiang Tan, Hui-Hui Zeng^* . Synergistic effect of ethaselen and cisplatin treatment against tumor cell lines [J]. , 2009, 18(4): 337-341.

Metrics

Viewed

Full text

Abstract

Comments

Abstract
References
Related Articles
Recommended Articles
Metrics
Comments

TOP